phosphonoacetic acid has been researched along with Electrolytes in 1 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 5.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 1.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ringdén, O | 1 |
| Lönnqvist, B | 1 |
| Paulin, T | 1 |
| Ahlmén, J | 1 |
| Klintmalm, G | 1 |
| Wahren, B | 1 |
| Lernestedt, JO | 1 |
1 other study available for phosphonoacetic acid and Electrolytes
| Article | Year |
|---|---|
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Electrolytes | 1986 |